RT Journal Article
T1 Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients
A1 González-Salvatierra, Sheila
A1 García-Fontana, Cristina
A1 Andújar-Vera, Francisco
A1 Grau-Perales, Alejandro Borja
A1 Martínez-Heredia, Luis
A1 Avilés-Pérez, María Dolores
A1 Hayón-Ponce, María
A1 Iglesias-Baena, Iván
A1 Riquelme-Gallego, Blanca
A1 Muñoz-Torres, Manuel
A1 García-Fontana, Beatriz
K1 Biomarker
K1 Diabetic kidney disease
K1 Kidney function impairment
K1 Osteoglycin
K1 Type 2 diabetes
K1 Biomarcadores
K1 Nefropatías diabéticas
K1 Diabetes Mellitus Tipo 2
AB Osteoglycin (OGN) could be a biomarker of mild kidney function impairment in type 2 diabetes (T2D). Our study aimed to determine the association between serum OGN and impaired kidney function risk in T2D patients and to analyze its potential role as an estimator of kidney disturbances in this population. This cross-sectional study included 147 T2D patients (65 ± 8 years, 58.5% males), and 75 healthy controls (63 ± 10 years, 36% males). Circulating OGN levels were determined by ELISA. Linear regression modeling was performed to determine the variables influencing circulating OGN, and an ROC curve was plotted to assess the usefulness of OGN as an estimator of diabetic kidney disease risk. Circulating OGN was significantly increased in T2D patients compared to controls (18.41 (14.45-23.27) ng/mL vs. 8.74 (7.03-12.35) ng/mL; p < 0.001). We found a progressive increase in serum OGN according to the severity of kidney impairment in T2D patients (normal kidney function: 16.14 (12.13-20.48) ng/mL; mildly impaired kidney function: 19.15 (15.78-25.90) ng/mL; moderate impaired kidney function: 21.80 (15.06-29.22) ng/mL; p = 0.006). Circulating OGN was an independent estimator of mildly impaired kidney function risk in T2D patients. We suggest that serum OGN could act as an albuminuria-independent biomarker of incipient kidney dysfunction in T2D patients.
PB MDPI
YR 2021
FD 2021-05-20
LK http://hdl.handle.net/10668/3536
UL http://hdl.handle.net/10668/3536
LA en
NO González-Salvatierra S, García-Fontana C, Andújar-Vera F, Grau-Perales AB, Martínez-Heredia L, Avilés-Pérez MD, et al. Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients. J Clin Med. 2021 May 20;10(10):2209
DS RISalud
RD Apr 17, 2025